These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20470188)

  • 1. Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.
    Wink LK; Plawecki MH; Erickson CA; Stigler KA; McDougle CJ
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):481-94. PubMed ID: 20470188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy to control behavioral symptoms in children with autism.
    Doyle CA; McDougle CJ
    Expert Opin Pharmacother; 2012 Aug; 13(11):1615-29. PubMed ID: 22550944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders.
    Wink LK; Erickson CA; McDougle CJ
    Curr Treat Options Neurol; 2010 Nov; 12(6):529-38. PubMed ID: 20848330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
    Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autism and associated behavioral disorders: pharmacotherapeutic intervention.
    Gilman JT; Tuchman RF
    Ann Pharmacother; 1995 Jan; 29(1):47-56. PubMed ID: 7711345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders.
    Findling RL
    J Clin Psychiatry; 2005; 66 Suppl 10():26-31. PubMed ID: 16401147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.
    Miyaoka T; Wake R; Furuya M; Liaury K; Ieda M; Kawakami K; Tsuchie K; Inagaki T; Horiguchi J
    BMC Psychiatry; 2012 Nov; 12():215. PubMed ID: 23194148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autism and other pervasive developmental disorders: exploring the dimensional view.
    Myhr G
    Can J Psychiatry; 1998 Aug; 43(6):589-95. PubMed ID: 9729686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.
    Brodkin ES; McDougle CJ; Naylor ST; Cohen DJ; Price LH
    J Child Adolesc Psychopharmacol; 1997; 7(2):109-21. PubMed ID: 9334896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Copper and Zinc Plasma Concentration and the Efficacy of Zinc Therapy in Individuals with Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and Autism.
    Russo AJ; Devito R
    Biomark Insights; 2011; 6():127-33. PubMed ID: 22174567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
    Posey DJ; Guenin KD; Kohn AE; Swiezy NB; McDougle CJ
    J Child Adolesc Psychopharmacol; 2001; 11(3):267-77. PubMed ID: 11642476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redefining autism spectrum disorder using DSM-5: the implications of the proposed DSM-5 criteria for autism spectrum disorders.
    Young RL; Rodi ML
    J Autism Dev Disord; 2014 Apr; 44(4):758-65. PubMed ID: 24057130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation.
    McDougle CJ; Brodkin ES; Naylor ST; Carlson DC; Cohen DJ; Price LH
    J Clin Psychopharmacol; 1998 Feb; 18(1):62-6. PubMed ID: 9472844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence and prevalence of pervasive developmental disorders: a Danish population-based study.
    Lauritsen MB; Pedersen CB; Mortensen PB
    Psychol Med; 2004 Oct; 34(7):1339-46. PubMed ID: 15697060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008.
    ;
    MMWR Surveill Summ; 2012 Mar; 61(3):1-19. PubMed ID: 22456193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders.
    Huerta M; Bishop SL; Duncan A; Hus V; Lord C
    Am J Psychiatry; 2012 Oct; 169(10):1056-64. PubMed ID: 23032385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological treatments in patients with pervasive developmental disorders: A review].
    Béhérec L; Quilici G; Rosier A; Gerardin P; Campion D; Guillin O
    Encephale; 2014 Apr; 40(2):188-96. PubMed ID: 24369879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use.
    Martin A; Scahill L; Klin A; Volkmar FR
    J Am Acad Child Adolesc Psychiatry; 1999 Jul; 38(7):923-31. PubMed ID: 10405512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gender dysphoria in pervasive developmental disorders].
    Tateno M; Ikeda H; Saito T
    Seishin Shinkeigaku Zasshi; 2011; 113(12):1173-83. PubMed ID: 22352003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetics of autism.
    Muhle R; Trentacoste SV; Rapin I
    Pediatrics; 2004 May; 113(5):e472-86. PubMed ID: 15121991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.